NDM Pharma provides POC for NMD670

Researchers at NDM Pharma A/S and Aarhus University have demonstrated that their oral CIC-1 blocker NMD670 restores crosstalk between neurons and muscles in Myasthenia gravis.

Roche opens €90m gene therapy development centre

Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich. <br /><br /><br />

AstraZeneca to take over Fusion Therapeutics Inc

British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.

Senisca Ltd raises £3.7m seed money

Exeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.

Relation Therapeutics Ltd bags US$35m in seed financing.

London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.

Researcher find potential target for atherosclerosis

TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.

Obesity: Arecor Therapeutics partners with TRx Biosciences

British companies Arecor Therapeutics plc and TRx Biosciences Ltd combine their technologies to formulate an oral GLP-1 receptor agonist with enhanced bioavailability<br />&nbsp;&nbsp;&nbsp;

Scientist create non-digestible aptamer

German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.

Scientists create non-digestible aptamer

German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.